On October 15, 2018 Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO), a company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology and gene therapies for rare diseases, reported the appointment of Martina A. Sersch, M.D., Ph.D., as Chief Medical Officer ("CMO") (Press release, Mustang Bio, OCT 15, 2018, View Source [SID1234530345]). Dr. Sersch will oversee the clinical development of Mustang’s pipeline in CAR T technology and gene therapies. Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, "We are delighted to welcome Martina to the Mustang leadership team. Her extensive global immuno-oncology drug
development expertise and vast array of experience in bringing innovative oncology products to market will help guide Mustang’s clinical development efforts and regulatory strategies in an exciting time of growth for the company."
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Sersch is an experienced drug developer and physician with specialty training in oncology, infectious and tropical diseases. She has more than 17 years of experience in early- and late-stage clinical development in academia and industry. Prior to joining Mustang, Dr. Sersch served as executive director at Amgen, where she successfully led supplemental Biologics License Application filings in the area of hematology, as well as indication strategies for early- and late-stage compounds in hematology. Prior to Amgen, Dr. Sersch held positions of increasing responsibility on regional and global levels in oncology drug development, including novel immuno-oncology drugs at IRAD Oncology, Genentech, Roche and Pfizer. At Roche, Dr. Sersch was instrumental in the biologics strategy, where she led initiatives globally and regionally with a specific focus in Asia Pacific and China, including supporting the development of regional guidelines for drug development. Dr. Sersch obtained her medical and graduate degrees from Heidelberg University in Germany and subsequently trained in England, South Africa and the United States.
Dr. Sersch said, "I am thrilled to join Mustang to help advance the development of its CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as its lentiviral gene therapy for XSCID. I look forward to working with the Mustang team as we strive to deliver promising new treatment options for patients and their families in areas of unmet medical need."